Glioblastoma is one of the most aggressive and hard-to-treat forms of brain cancer in adults. A major reason why current therapies like chemotherapy often fail is that the Tumour is made up of many different cells that behave very differently from one another. Some cells die after treatment, while others survive and allow the cancer to grow back. New research helps explain why this internal chaos exists and offers a promising way to make glioblastoma cells more vulnerable to chemotherapy.
Understanding Tumour Chaos and Treatment Resistance
In most cancers, treatment works by damaging the DNA of tumour cells so that they can no longer survive. In glioblastoma, however, cells produce varying amounts of a DNA repair protein called MGMT (Methyl-Guanine Methyl Transferase).MGMT allows cells to fix the damage caused by chemotherapy, which makes them resistant to treatment. The more MGMT a cell produces, the more likely it is to survive. Because different cells within the same tumour make different amounts of MGMT, some cells resist therapy while others are killed.
Research Details
The research team led by Dr Clark C. Chen, MD, PhD, Director of the Brain Tumour Program in the Department of Neurosurgery at Brown University Health, took a fresh approach. Instead of looking at the average behaviour of all tumour cells, they focused on the differences between individual cells within the tumour. They discovered that a small molecule called miR-181d plays a central role in controlling how much MGMT each cell makes.
When the level of miR-181d drops, which happens during chemotherapy, the differences between cells become even wider. Some produce a lot of MGMT and survive, while others make very little and die. The researchers found that delivering miR-181d back into the tumour can reduce this variability. In effect, miR-181d makes the cells behave more uniformly, which increases their overall sensitivity to chemotherapy, meaning more cancer cells can be killed during treatment.
Read More: Neuroimmune Interactions: From the brain to the Immune system
Authors’ Perspective
Dr. Clark C. Chen and collaborators, including Dr Gatikrushna Singh from the University of Minnesota, explain that this discovery offers a new way of thinking about glioblastoma treatment. Rather than trying to target the average tumour behaviour, their work shows that reducing the internal cellular chaos can make traditional therapies more effective. Dr Singh notes that the finding opens the doors to gene therapy strategies that could make glioblastoma more treatable in the near future.
The study was carried out through a joint effort by researchers from Brown University Health, the University of Minnesota VisiCELL Medical Inc., Stanford University and Johns Hopkins University. The research was supported by organisations involved in cancer and neuroscience research. This support highlights the importance of experts from different fields working together to better understand and treat a complex and serious disease like glioblastoma.
Major findings
The research shows that a molecule called miR-181d plays a key role in controlling how much MGMT is produced in glioblastoma cells. Differences in MGMT levels from one tumour cell to another help explain why some cells survive chemotherapy while others are destroyed. When miR-181d is reintroduced, it helps stabilise cell behaviour by reducing this variation, making tumour cells respond more uniformly to treatment. This approach points to a promising new strategy for improving existing therapies by targeting the internal differences within tumours rather than focusing only on the tumour’s average response.
Conclusion
This study offers a compelling new perspective on treating glioblastoma by addressing the chaotic differences within tumour cells that allow some cells to resist therapy. By stabilising levels of miR-181d, researchers were able to makemore tumour cells respond to chemotherapy, which could lead to more effective treatment outcomes. The work emphasises that understanding and reducing internal tumour variability could be just as important as developing new drugs. Continued research and clinical development could one day make this approach a part of standard glioblastoma treatment.
Leave feedback about this